ATE475706T1 - Abgeschwächter dengue-serotyp-2-stamm - Google Patents

Abgeschwächter dengue-serotyp-2-stamm

Info

Publication number
ATE475706T1
ATE475706T1 AT06755943T AT06755943T ATE475706T1 AT E475706 T1 ATE475706 T1 AT E475706T1 AT 06755943 T AT06755943 T AT 06755943T AT 06755943 T AT06755943 T AT 06755943T AT E475706 T1 ATE475706 T1 AT E475706T1
Authority
AT
Austria
Prior art keywords
strain
dengue serotype
attenuated dengue
attenuated
serotype
Prior art date
Application number
AT06755943T
Other languages
English (en)
Inventor
Richard Kinney
Claire Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Sanofi Pasteur
Ct S For Disease Control And P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Ct S For Disease Control And P filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE475706T1 publication Critical patent/ATE475706T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/08Inactivation or attenuation by serial passage of virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24164Methods of inactivation or attenuation by serial passage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT06755943T 2005-06-17 2006-06-07 Abgeschwächter dengue-serotyp-2-stamm ATE475706T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69127405P 2005-06-17 2005-06-17
PCT/IB2006/001513 WO2006134443A1 (en) 2005-06-17 2006-06-07 Dengue serotype 2 attenuated strain

Publications (1)

Publication Number Publication Date
ATE475706T1 true ATE475706T1 (de) 2010-08-15

Family

ID=37103341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755943T ATE475706T1 (de) 2005-06-17 2006-06-07 Abgeschwächter dengue-serotyp-2-stamm

Country Status (18)

Country Link
US (4) US7641908B2 (de)
EP (1) EP1891210B1 (de)
JP (1) JP5075120B2 (de)
KR (2) KR101582163B1 (de)
CN (1) CN101238209B (de)
AR (1) AR053914A1 (de)
AT (1) ATE475706T1 (de)
AU (1) AU2006257621B2 (de)
BR (1) BRPI0613287A2 (de)
CA (1) CA2611954C (de)
DE (1) DE602006015807D1 (de)
IL (1) IL188068A0 (de)
MX (1) MX2007015872A (de)
MY (2) MY161457A (de)
NO (1) NO20076360L (de)
TW (1) TWI375722B (de)
WO (1) WO2006134443A1 (de)
ZA (1) ZA200710752B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101238209B (zh) * 2005-06-17 2013-02-13 赛诺菲巴斯德有限公司 登革血清型2减毒株
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN101139638B (zh) * 2007-05-08 2010-05-26 深圳太太基因工程有限公司 一种用于检测登革病毒ⅲ型核苷酸片段的引物和探针序列
EP2589392B1 (de) 2008-03-05 2016-11-30 Sanofi Pasteur Stabilisierungsverfahren für eine adjuvanshaltige Impfstoffzusammensetzung
EP2143440A1 (de) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilisierungssubstanz und Impfzusammensetzung, die ein oder mehrere abgeschwächte lebende Flaviviridae enthält
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MY184428A (en) * 2009-06-01 2021-04-01 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
CN102755642B (zh) * 2012-07-13 2014-01-08 中国食品药品检定研究院 一种炭疽疫苗的制备方法
SG11201500439RA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
JP2015524421A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールSanofipasteur ワクチン組成物
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
CA3177574A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
SG11201510266SA (en) 2013-06-21 2016-01-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
CN103382509A (zh) * 2013-07-17 2013-11-06 浙江国际旅行卫生保健中心 逆转录-环介导等温扩增检测登革2型病毒的试剂及检测方法
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
AU2015369875A1 (en) 2014-12-22 2017-06-15 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
KR102297300B1 (ko) * 2015-11-27 2021-09-02 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
EP1159968B1 (de) * 2000-05-30 2008-10-29 Mahidol University Attenuierte Stammen von Denguevirus und ihre Verwendungen in Impfstoffzusammensetzungen
AU2002223560B2 (en) * 2000-09-25 2006-06-29 Polymun Scientific Immunbiologische Forschung Gmbh Live influenza vaccine and method of manufacture
ES2533085T3 (es) * 2001-05-22 2015-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
WO2003092592A2 (en) * 2002-05-03 2003-11-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
CN101238209B (zh) * 2005-06-17 2013-02-13 赛诺菲巴斯德有限公司 登革血清型2减毒株

Also Published As

Publication number Publication date
AU2006257621A1 (en) 2006-12-21
KR101582163B1 (ko) 2016-01-05
US20100174057A1 (en) 2010-07-08
US7641908B2 (en) 2010-01-05
US8067566B2 (en) 2011-11-29
CA2611954C (en) 2014-01-28
JP5075120B2 (ja) 2012-11-14
MY144542A (en) 2011-09-30
KR20140019034A (ko) 2014-02-13
JP2008546383A (ja) 2008-12-25
EP1891210A1 (de) 2008-02-27
BRPI0613287A2 (pt) 2010-12-28
TWI375722B (en) 2012-11-01
US20150031857A1 (en) 2015-01-29
DE602006015807D1 (de) 2010-09-09
WO2006134443A1 (en) 2006-12-21
TW200738881A (en) 2007-10-16
US8795688B2 (en) 2014-08-05
KR20080018271A (ko) 2008-02-27
US20070026016A1 (en) 2007-02-01
CN101238209A (zh) 2008-08-06
EP1891210B1 (de) 2010-07-28
CA2611954A1 (en) 2006-12-21
US20120083585A1 (en) 2012-04-05
IL188068A0 (en) 2008-03-20
NO20076360L (no) 2008-03-11
MY161457A (en) 2017-04-14
ZA200710752B (en) 2008-12-31
CN101238209B (zh) 2013-02-13
MX2007015872A (es) 2008-04-21
AR053914A1 (es) 2007-05-23
AU2006257621B2 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
ATE475706T1 (de) Abgeschwächter dengue-serotyp-2-stamm
IL188041A0 (en) Dengue serotype 1 attenuated strain
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
DE602007009284D1 (de) 3-aza-bicycloä3.1.0ühexanderivate
DE502006000770D1 (de) Konservierungsmittel
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
ATE535505T1 (de) Landwirtschaftliche zusammensetzung
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DK1741339T3 (da) Pesticid sammensætning
FI20055434A (fi) Refraktometri
DK1865813T3 (da) Fastgørelsesbøjle
FI20055407A0 (fi) Kalanteri
DE502006003938D1 (de) Roststab
ATE538121T1 (de) 1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel
ATE412728T1 (de) Bleichmittel
DE502005007729D1 (de) Kalander
UA13036S (uk) Барна стійка
ITMI20050295U1 (it) Tovagliette sottopiatto migliorate
DE502006001048D1 (de) Kombileiste
TH81898B (th) ราวตากผ้า
ITFR20050004U1 (it) Traliccio "conte" muniti di due piattinecon tondino distanziatore
ITDP20060026A1 (it) Multisnodo 1
ITDP20060016A1 (it) Multisnodo 2
UA12880S (uk) Диван

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties